0001104659-22-108996.txt : 20221017 0001104659-22-108996.hdr.sgml : 20221017 20221017060705 ACCESSION NUMBER: 0001104659-22-108996 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221017 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221017 DATE AS OF CHANGE: 20221017 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 221312486 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2228338d1_8k.htm FORM 8-K
0001408443 false A8 00-0000000 QC 0001408443 2022-10-17 2022-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

October 17, 2022

 

 

 

MILESTONE PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its Charter)

 

 

 

Québec   001-38899   Not applicable
(state or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

1111 Dr. Frederik-Philips Boulevard,        
Suite 420        
Montréal, Québec CA       H4M 2X6
(Address of principal executive offices)       (Zip Code)

 

Registrant's telephone number, including area code: (514) 336-0444

 

 

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares   MIST   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On October 17, 2022, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing topline results from Phase 3 RAPID clinical trial of etripamil. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In connection with the announcement, the Company will host a call and webcast on October 17, 2022 at 8:00 a.m. E.T. Call details are contained in the press release. Accompanying slides may be accessed through the “Investors” section of the Company's website at www.milestonepharma.com.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
99.1   Press release, dated October 17, 2022
104   Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MILESTONE PHARMACEUTICALS INC.
     
  By: /s/ Amit Hasija
    Amit Hasija
    Chief Financial Officer
     

Dated: October 17, 2022

 

 EX-99.1 2 tm2228338d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of
Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

 

─Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
─Consistent safety and tolerability data support potential self-administration of etripamil
─Analyses of pooled data show statistically significant reduction in medical interventions and visits to the emergency department
─Company plans to submit an NDA to the U.S. FDA in mid-2023
─Conference call and webcast to be held today at 8:00 a.m. Eastern Time

 

MONTREAL and CHARLOTTE, N.C., October 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced positive topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil, the Company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

 

“PSVT is an unpredictable, disruptive burden on patients, with current interventions restricted to the costly and inconvenient acute care setting,” said Bruce Stambler, M.D., F.H.R.S., Director of Cardiac Arrhythmia Research and Education, Piedmont Heart Institute, Atlanta, GA. “I am highly encouraged by the findings from the RAPID trial, which demonstrate that patients who administered etripamil converted to normal sinus rhythm significantly more often than placebo patients without experiencing serious adverse events, and independent of medical supervision. These data further support the potential for etripamil to deliver a clinically meaningful benefit to patients and an important and valuable tool for their physicians.”

 

“Today marks an important achievement for Milestone and for patients with PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that etripamil, if approved, has the potential to empower patients to take control of their condition as well as provide value to the healthcare system, in part by reducing visits to the Emergency Department. We look forward to working with the U.S. Food and Drug Administration (FDA) to make available what we believe is the first of its kind, self-administered therapy. On behalf of the Milestone team, I would like to thank the patients, their caregivers, and the healthcare professionals who took part in the RAPID trial.”

 

The multi-center, randomized, double-blind, placebo-controlled RAPID trial enrolled 706 patients across clinical sites in North America and Europe. Patients were randomized 1:1 to a nasal spray of either etripamil or placebo without medical monitoring. To maximize the potential treatment effect of etripamil, patients who did not experience symptom relief within 10 minutes were directed to self-administer a repeat dose of study drug. The RAPID trial achieved its primary endpoint, with patients taking etripamil demonstrating a highly statistically significant and clinically meaningful difference in time to PSVT conversion compared to placebo. A Kaplan Meier analysis shows a statistically significantly greater proportion of patients who took etripamil converted within thirty minutes compared to placebo (64.3% vs. 31.2%; hazard ratio [HR] = 2.62; 95% CI 1.66, 4.15; p<0.001). In addition, the median time to conversion for patients in RAPID who took etripamil was three times faster than for patients who took placebo. Statistically significant reductions in time to conversion in patients who took etripamil were evident early and persisted throughout the observation window of the study compared to placebo.

 

The safety and tolerability data from the RAPID trial continue to support the potential self-use of etripamil, with findings consistent with those observed in prior trials. The most common randomized treatment emergent adverse events (RTEAEs), adverse events (AEs) which occurred within 24 hours of study drug administration, were related to the nasal administration site. Overall, the majority of RTEAEs were reported as mild (68%) to moderate (31%). There were no reported serious AEs related to etripamil. To date, the Company’s overall PSVT clinical program has resulted in more than 1,600 unique patient exposures of etripamil doses of ≥70 mg.

 

 

 

 

Analyses of pooled data from the NODE-301 and RAPID trials show that etripamil treatment provided a statistically significant reduction in the use of additional medical interventions, and a statistically significant reduction in visits to the emergency department.

 

Full results from the Phase 3 RAPID clinical trial are expected to be presented at an upcoming medical meeting and submitted to a peer-reviewed journal for publication.

 

As previously communicated, the Company believes results from the RAPID trial together with the data from the already completed NODE-301 trial could fulfill the efficacy requirement for a New Drug Application (NDA) submission for etripamil in patients with PSVT. The Company continues to enroll patients in the open label NODE-303 safety trial and plans to submit an NDA application in mid-2023 pending agency feedback.

 

Conference Call and Webcast

 

Milestone will host a conference call and webcast to discuss the results of the RAPID trial today, October 17, 2022 at 8:00 a.m. ET. To access the live call by phone, dial (877) 870-4263 (domestic) or (412) 317-0790 (international); the conference ID is 10171280. A live audio webcast of the event and accompanying slides may also be accessed through the “Investors” section of Milestone’s website at www.milestonepharma.com. A replay of the webcast will be available for one year following the event.

 

About Paroxysmal Supraventricular Tachycardia

 

Paroxysmal supraventricular tachycardia (PSVT) is a condition affecting approximately two million Americans that is characterized by intermittent episodes of a rapid heartbeat that starts and stops suddenly. Episodes of supraventricular tachycardia (SVT) are often associated with symptoms such as palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, and anxiety. Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT. However, these medications must be administered under medical supervision, usually in an emergency department or other acute care setting.

 

About Etripamil

 

Etripamil, a new chemical entity, is Milestone’s lead investigational product. It is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient, etripamil has the potential to shift the current treatment experience for many patients from the emergency department to a medically unsupervised setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials ongoing in paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial that is underway in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).

 

About Milestone Pharmaceuticals

 

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “design,” “develop,” “estimate,” “expect,” “further,” “look forward,” “ongoing,” “plan,” “potential,” “progress,” “will,” “would,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential efficacy, safety and tolerability of etripamil; the potential of etripamil to deliver a clinically meaningful benefit to patients with PSVT in the home-setting environment and to empower patients to take control of their condition as well as provide value to the healthcare system; the design, progress, timing, scope and results of the RAPID trial; Milestone’s ability to execute on the remainder of the PSVT program; the presentation and publication of unblind RAPID results and topline data with respect to the Company’s RAPID trial and the timing of such presentation and publication; the timing of Milestone’s NDA application, the ability of the results from the RAPID study to fulfil the efficacy requirements of such NDA application and the timing of agency feedback on the application; and Milestone’s ongoing plans to study etripamil in atrial fibrillation patients and estimates about the addressable market and commercial potential for treatments of atrial fibrillation with rapid ventricular rate. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion and evaluation of clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT, AFib-RVR or other indications, among others, as well as risks related to pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2021, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Contact

 

David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com

 

 

 

 EX-101.SCH 3 mist-20221017.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20221017_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20221017_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2228338d1_ex99-1img001.jpg GRAPHIC begin 644 tm2228338d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 17, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 17, 2022
Entity File Number 001-38899
Entity Registrant Name MILESTONE PHARMACEUTICALS INC.
Entity Central Index Key 0001408443
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code A8
Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard
Entity Address, Address Line Two Suite 420
Entity Address, City or Town Montréal
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4M 2X6
City Area Code 514
Local Phone Number 336-0444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol MIST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2228338d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2022-10-17 2022-10-17 iso4217:USD shares iso4217:USD shares 0001408443 false A8 00-0000000 QC 8-K 2022-10-17 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - tm2228338d1_8k.htm 21, 23 tm2228338d1_8k.htm mist-20221017.xsd mist-20221017_lab.xml mist-20221017_pre.xml tm2228338d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2228338d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2228338d1_8k.htm" ] }, "labelLink": { "local": [ "mist-20221017_lab.xml" ] }, "presentationLink": { "local": [ "mist-20221017_pre.xml" ] }, "schema": { "local": [ "mist-20221017.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20221017", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228338d1_8k.htm", "contextRef": "From2022-10-17to2022-10-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://milestonepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228338d1_8k.htm", "contextRef": "From2022-10-17to2022-10-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-108996-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-108996-xbrl.zip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end